Anacor Pharmaceuticals, Inc. (ANAC): Anders D Hove , director of Anacor Pharmaceuticals, Inc. sold 353,881 shares on May 16, 2016. The Insider selling transaction was reported by the company on May 18, 2016 to the Securities and Exchange Commission. The shares were sold at $99.65 per share for a total value of $35241708 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 29, 2016, Ryan T Sullivan (EVP and General Counsel) sold 3,125 shares at $66.33 per share price.On Apr 11, 2016, Anders D Hove (director) sold 229,301 shares at $72.29 per share price.Also, On Mar 23, 2016, Paul L Berns (President and CEO) sold 37,500 shares at $60.17 per share price.On Mar 4, 2016, Vincent P Ippolito (EVP & Chief Commercial Officer) sold 9,000 shares at $63.72 per share price.
Shares of Anacor Pharmaceuticals Inc (ANAC) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -0.07 points or -0.07% at $99.49 with 92,62,001 shares getting traded. Post opening the session at $99.59, the shares hit an intraday low of $99.24 and an intraday high of $99.67 and the price vacillated in this range throughout the day. The company has a market cap of $4,514 M and the number of outstanding shares has been calculated to be 4,53,66,886 shares. The 52-week high of Anacor Pharmaceuticals Inc is $156.925 and the 52-week low is $52.
Company has been under the radar of several Street Analysts.Anacor Pharmaceuticals Inc is Downgraded by Mizuho to Neutral and the brokerage firm has set the Price Target at $99.25. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on May 18, 2016.Anacor Pharmaceuticals Inc is Reiterated by Wedbush to Outperform while Lowering the Price Target of the company shares to $ 148 from a previous price target of $152 . The Rating was issued on May 3, 2016.Anacor Pharmaceuticals Inc is Initiated by Mizuho to Buy and the brokerage firm has set the Price Target at $103. The Rating was issued on Mar 11, 2016.
Anacor Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on discovering developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company’s lead product candidate AN2728 is an investigational non-steroidal topical PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis and psoriasis. The Company’s product KERYDIN (tavaborole) topical solution is an oxaborole antifungal. The Company also has a pipeline of other internally discovered topical and systemic boron-based compounds in early stages of research and development which include AN3365. The Company’s compound AN5568 (SCYX-7158) is licensed to Drugs for Neglected Diseases initiative (DNDi) for the potential treatment of human African trypanosomiasis (sleeping sickness).